Alnylam Pharmace. buy Truist Financial Co.
Start price
08.01.26
/
50%
€343.00
Target price
08.01.27
€454.00
Performance (%)
-16.82%
Price
20.02.26
€285.30
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -16.82%. This prediction currently runs until 08.01.27. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 11.008% | 11.008% |
| iShares Core DAX® | 1.066% | -0.525% |
| iShares Nasdaq 100 | -0.493% | -4.055% |
| iShares Nikkei 225® | -2.028% | 6.911% |
| iShares S&P 500 | -0.103% | -2.366% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Truist Financial Corporation from $535.00 to $530.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€418.20
17.10.25
17.10.25
€457.16
17.10.26
17.10.26
-31.78%
20.02.26
20.02.26
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€275.00
21.07.25
21.07.25
€331.29
21.07.26
21.07.26
3.75%
20.02.26
20.02.26